Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Subscribe To Our Newsletter & Stay Updated
